Alvotech Revenue and Competitors

Reykjavik, Iceland

Location

$450M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Alvotech's estimated annual revenue is currently $250.2M per year.(i)
  • Alvotech's estimated revenue per employee is $248,000
  • Alvotech's total funding is $450M.

Employee Data

  • Alvotech has 1009 Employees.(i)
  • Alvotech grew their employee count by 7% last year.

Alvotech's People

NameTitleEmail/Phone
1
CMO Technology Transfer Lead Drug ProductsReveal Email/Phone
2
Interim Chief Quality OfficerReveal Email/Phone
3
Chief Quality OfficerReveal Email/Phone
4
Chief IP Counsel & Deputy General Counsel; Alvotech USA Inc.Reveal Email/Phone
5
VPReveal Email/Phone
6
VP Program and Alliance ManagementReveal Email/Phone
7
SVP Clinical, Regulatory and Late Stage DevelopmentReveal Email/Phone
8
Head Supply Chain OperationsReveal Email/Phone
9
VP Clinical OperationsReveal Email/Phone
10
Head Commissioning and QualificationReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$55170M566975%$10.9M$240.2B
Add Company

What Is Alvotech?

Alvotech was founded in 2013, with the clear mission to become a global leader in Biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. We have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. Our in-house development and manufacturing platform located at four sites across Europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in Reykjavik Iceland, ensures high quality and cost-effective production. We are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. We believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. We are dedicated to making people's lives better by improving access to and lowering cost of care. Because if there is a cure it should be available to everyone.

keywords:N/A

$450M

Total Funding

1009

Number of Employees

$250.2M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Alvotech News

2022-04-20 - Oaktree Acquisition II Scores $250M Backstop to Support ...

Alvotech is a global biopharmaceutical company focused on the development and manufacture of biosimilar medicines.

2022-04-19 - Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange

Alvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company's capital position and to replace any...

2022-04-06 - Alvotech and AbbVie Resolve Disputes Relating to Alvotech’s ...

Alvotech Holdings S.A. (“Alvotech”) announced today that it has resolved all intellectual property disputes with AbbVie in Europe related to...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$517.8M20633%N/A